Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s traded shares stood at 806,421 during the last session, with the company’s beta value hitting 1.07. At the close of trading, the stock’s price was $48.33, to imply a decline of -0.88% or -$0.43 in intraday trading. The GBT share’s 52-week high remains $83.69, putting it -73.16% down since that peak but still an impressive +24.5% since price per share fell to its 52-week low of $36.49. The company has a valuation of $2.99 Billion, with an average of 776.81 Million shares in intraday trading volume over the past 10 days and average of 1.1 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Overweight for Global Blood Therapeutics, Inc. (GBT), translating to a mean rating of 1.9. Of 20 analyst(s) looking at the stock, none analyst(s) give GBT a Sell rating. None of those analysts rate the stock as Overweight while 5 advise Hold as 15 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.94.
Global Blood Therapeutics, Inc. (NASDAQ:GBT) trade information
After registering a -0.88% downside in the last session, Global Blood Therapeutics, Inc. (GBT) has traded green over the past five days. The stock hit a weekly high of $50.98 this Tuesday, Feb 16, jumping 5.2% in its intraday price action. The 5-day price performance for the stock is 1.66%, and -4.96% over 30 days. With these gigs, the year-to-date price performance is 11.59%. Short interest in Global Blood Therapeutics, Inc. (NASDAQ:GBT) saw shorts transact 11.36 Million shares and set a 10.33 days time to cover.
Analysts on Wall Street suggest a consensus price target of $84.11, implying an increase of 74.03% to the stock’s current value. The extremes give us $45 and $138 for target low and target high price respectively. As such, GBT has been trading 185.54% off suggested target high and -6.89% from its likely low.
Global Blood Therapeutics, Inc. (GBT) estimates and forecasts
Looking at statistics comparing Global Blood Therapeutics, Inc. share performance against respective industry, we note that the company has outperformed competitors. Global Blood Therapeutics, Inc. (GBT) shares are -25.77% down over the last 6 months, with its year-to-date growth rate higher than industry average at 15.07% against 14%. But the analysts are intensifying their growth estimates for the 2021 fiscal year. Revenue is forecast to grow 40.9% this quarter before jumping 20.8% for the next one. The rating firms project that company’s revenue will grow 5660.9% compared to the previous financial year.
Revenue forecast for the current quarter as set by 18 analysts is $39.03 Million. Meanwhile, for the quarter ending March 01, 2021, a total of 15 analyst(s) estimate revenue growth to $45.48 Million. Earnings reports from the last fiscal year show that sales brought in $2.11 Million and $14.12 Million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 1751.5% before jumping 222.1% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings fell an estimated -33.2% for the past 5-year period. While 2021 is set for a -34.3% return in earnings, projections for the next 5 years are at 37% annually.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Global Blood Therapeutics, Inc. (NASDAQ:GBT)’s Major holders
Global Blood Therapeutics, Inc. insiders hold 1.77% of total outstanding shares, with institutional holders owning 108.4% of the shares at 110.36% float percentage. In total, 343 institutions holds shares in the company, led by Bank of America Corporation. As of Dec 30, 2020, the company held over 6.07 Million shares (or 9.82% of shares), all amounting to roughly $262.73 Million.
The next major institution holding the largest number of shares is Perceptive Advisors Llc with 5.8 Million shares, or about 9.39% of shares outstanding. As of the market price on Sep 29, 2020, these shares were worth $319.87 Million.